Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy

被引:0
作者
Li, Yun [1 ,2 ]
Lai, Yanzhen [1 ,2 ]
Luo, Xuqiang [1 ,2 ]
Wu, Jian [1 ,2 ]
Wu, Kunpeng [1 ,2 ]
Ma, Haiqing [1 ,2 ,3 ]
机构
[1] Heyuan Peoples Hosp, Guangdong Prov Peoples Hosp, Dept Oncol, Heyuan Hosp, Heyuan, Guangdong, Peoples R China
[2] Heyuan Peoples Hosp, Heyuan Key Lab Mol Diag & Dis Prevent & Treatment, Doctors Stn Guangdong Prov, Heyuan, Guangdong, Peoples R China
[3] Southern Med Univ, Guangdong Prov Peoples Hosp, Med Res Inst, Guangdong Acad Med Sci,Med Res Ctr, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular cancer; radiotherapy; complete response; anlotinib; sindilizumab; RADIATION-THERAPY; SINTILIMAB PLUS; OPEN-LABEL; PHASE-II; IPILIMUMAB; IBI305;
D O I
10.3389/fonc.2024.1291131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The five-year recurrence rate of hepatocellular carcinoma (HCC) remains as high as 70%. A complete clinical response has not been observed without surgical resection. Here, we report a rare case of clinical complete response and long-term survival in a patient with massive HCC receiving treatment with immunotherapy, anti-angiogenic therapy, and radiotherapy.Case description A 38-year-old woman presented to our hospital for abdominal pain that persisted for 3 months. She was diagnosed as Barcelona Clinic Liver Cancer(BCLC) stage A, with a Cancer of the Liver Italian Program (CLIP) score of 3, American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging systems stage IB. She refused surgical resection and trans-arterial chemoembolization and accepted a non-invasive systematic treatment strategy involving immunotherapy, anti-angiogenic therapy, and radiotherapy. Her tumor burden decreased, and she experienced partial response before radiotherapy. Following radiotherapy, she experienced a complete clinical response and has been alive for more than 36 months after her initial presentation. She is currently alive.Conclusion A non-invasive systematic treatment strategy is a potential radical treatment option for patients with massive HCC.
引用
收藏
页数:6
相关论文
共 24 条
[1]   External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline [J].
Apisarnthanarax, Smith ;
Barry, Aisling ;
Cao, Minsong ;
Czito, Brian ;
DeMatteo, Ronald ;
Drinane, Mary ;
Hallemeier, Christopher L. ;
Koay, Eugene J. ;
Lasley, Foster ;
Meyer, Jeffrey ;
Owen, Dawn ;
Pursley, Jennifer ;
Schaub, Stephanie K. ;
Smith, Grace ;
Venepalli, Neeta K. ;
Zibari, Gazi ;
Cardenes, Higinia .
PRACTICAL RADIATION ONCOLOGY, 2022, 12 (01) :28-51
[2]   Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies [J].
Ben-Josef, E ;
Normalle, D ;
Ensminger, WD ;
Walker, S ;
Tatro, D ;
Ten Haken, RK ;
Knol, J ;
Dawson, LA ;
Pan, C ;
Lawrence, TS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8739-8747
[3]   Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 [J].
Cao, Wei ;
Chen, Hong-Da ;
Yu, Yi-Wen ;
Li, Ni ;
Chen, Wan-Qing .
CHINESE MEDICAL JOURNAL, 2021, 134 (07) :783-791
[4]   Efficacy and safety of radiotherapy for primary liver cancer [J].
Chen, Wenqi ;
Chiang, Chi-Leung ;
Dawson, Laura A. .
CHINESE CLINICAL ONCOLOGY, 2021, 10 (01)
[5]   Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC [J].
Chu, Tianqing ;
Zhong, Runbo ;
Zhong, Hua ;
Zhang, Bo ;
Zhang, Wei ;
Shi, Chunlei ;
Qian, Jialin ;
Zhang, Yanwei ;
Chang, Qing ;
Zhang, Xueyan ;
Dong, Yu ;
Teng, Jiajun ;
Gao, Zhiqiang ;
Qiang, Huiping ;
Nie, Wei ;
Zhao, Yiming ;
Han, Yuchen ;
Chen, Ya ;
Han, Baohui .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) :643-652
[6]   Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies [J].
Dawson, LA ;
McGinn, CJ ;
Normolle, D ;
Ten Haken, RK ;
Walker, S ;
Ensminger, W ;
Lawrence, TS .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2210-2218
[7]   Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity [J].
Ho, Won Jin ;
Zhu, Qingfeng ;
Durham, Jennifer ;
Popovic, Aleksandra ;
Xavier, Stephanie ;
Leatherman, James ;
Mohan, Aditya ;
Mo, Guanglan ;
Zhang, Shu ;
Gross, Nicole ;
Charmsaz, Soren ;
Lin, Dongxia ;
Quong, Derek ;
Wilt, Brad ;
Kamel, Ihab R. ;
Weiss, Matthew ;
Philosophe, Benjamin ;
Burkhart, Richard ;
Burns, William R. ;
Shubert, Chris ;
Ejaz, Aslam ;
He, Jin ;
Deshpande, Atul ;
Danilova, Ludmila ;
Stein-O'Brien, Genevieve ;
Sugar, Elizabeth A. ;
Laheru, Daniel A. ;
Anders, Robert A. ;
Fertig, Elana J. ;
Jaffee, Elizabeth M. ;
Yarchoan, Mark .
NATURE CANCER, 2021, 2 (09) :891-+
[8]  
Jelic S., 2010, Ann Oncol, V21, pv59, DOI DOI 10.1093/ANNONC/MDQ166
[9]   Sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma [J].
Jia, F. ;
Ren, Z. ;
Xu, J. ;
Shao, G. ;
Dai, G. ;
Liu, B. ;
Xu, A. ;
Yang, Y. ;
Wang, Y. ;
Zhou, H. ;
Chen, M. .
ANNALS OF ONCOLOGY, 2020, 31 :S692-S692
[10]   RADIATION ENHANCES REGULATORY T CELL REPRESENTATION [J].
Kachikwu, Evelyn L. ;
Iwamoto, Keisuke S. ;
Liao, Yu-Pei ;
DeMarco, John J. ;
Agazaryan, Nzhde ;
Economou, James S. ;
McBride, William H. ;
Schaue, Doerthe .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04) :1128-1135